One of the most remarkable — and least understood — events in cancer (oncology) is the spontaneous remission (SR) of cancer: the partial or complete disappearance of a malignancy in spite of conventional treatment.

Rare though it is, SR is documented and scientifically studied, and it holds important lessons for us at RCM Health and for our clients for how we understand the relationship between the body, the mind, and cancer.

I first learned about spontaneous remission of cancer when I took a course at Harvard with Dr. Herbert Benson. The lecturers identified a variable common amongst those with SR of cancer. Hopefulness. This always intrigued me. The power of intention, focus, and a commitment to healing and its very significant impact on our biology, including on cancer.

How Often Does It Happen?

Estimates suggest SR occurs in roughly 1 in 60,000 to 100,000 cancer cases — though many researchers believe the true rate is higher, as cases often go unreported or are misattributed to prior treatment.

The foundational research in this field, Spontaneous Regression of Cancer by Everson and Cole (1966), documented 176 well-verified cases and remains the cornerstone of the literature. Autopsy studies suggest subclinical tumors — particularly of the thyroid and prostate — may regress far more often than we recognize.

Which Cancers Are Most Affected?

SR has been reported across many tumor types. The most frequently documented include renal cell carcinoma (kidney cancer), neuroblastoma in infants, melanoma, follicular non-Hodgkin lymphoma, and certain leukemias in newborns.

Even occasional cases in breast, colorectal, cholangiocarcinoma, and lung cancer have been described, lending weight to the view that no cancer type is entirely exempt from the possibility of spontaneous remission of cancer.

What Triggers Spontaneous Remission?

No single mechanism accounts for all cases, and most researchers believe that spontaneous remission results from the interaction of multiple factors. The leading proposed mechanisms include:



•   Immune-mediated rejection — the most studied pathway, in which the body's T-cells and NK cells mount an effective anti-tumor response. Notably, several documented cases followed a high fever or serious infection, echoing the 19th-century observations of surgeon William Coley, who used bacterial toxins to stimulate immune responses in cancer patients.

•   Removal of a causative agent — gastric MALT lymphoma, for example, can resolve completely after eradication of H. pylori infection.

•   Tumor differentiation — infant neuroblastoma can mature into a benign ganglioneuroma, effectively ceasing to behave as cancer.

•   Epigenetic shifts — patients with the intention to heal through mind over body and with a very focused meditation practice are able to activate tumor suppressor genes like TP53, which have been turned off in cancer. The genes flip from turned off to turned on and act against the cancer.

Relevance to Modern Oncology

The rise of immunotherapy has renewed scientific interest in SR. Researchers studying PD-1/PD-L1 checkpoint inhibitors have noted that some cases of SR closely mirror what these drugs achieve pharmacologically — suggesting the body is, in rare circumstances, capable of doing on its own what medicine now attempts to replicate artificially.

SR cases have helped validate the immune surveillance model of cancer and informed the development of therapies now transforming oncology.

To learn more about RCM Health services and how we assist Clients with complex issues:

647-350-5500

info@rcmhealth.ca

Raymond Rupert

CEO 

RCM Health Consultancy Inc.

www.rcmhealth.ca